The multifaceted roles of the chemokines CCL2 and CXCL12 in osteophilic metastatic cancers

Midavaine, Élora; Côté, Jérôme; Sarret, Philippe

doi:10.1007/s10555-021-09974-2

Cited by 17 publications

(12 citation statements)

References 194 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The anti‐lung metastasis mechanisms of HDC‐DM were investigated by immunofluorescence. As shown in Figure 5e, the expression of CC motif chemokine ligand2 (CCL2), which was closely related to lung metastasis in breast cancer, [ 23 ] displayed a high level in the DTX group, while this phenomenon could be reversed by the CTL‐containing formulations, especially HDC‐DM+L. Besides CCL2, the E‐cadherin level in tumors was upregulated, with the matrix metalloproteinase (MMP)‐9 level downregulated, which meant that HDC‐DM+L inhibited the lung metastasis by regulating related signaling pathways (Figure 5f,g).…”

Section: Resultsmentioning

confidence: 99%

Promote Intratumoral Drug Release and Penetration to Counteract Docetaxel‐Induced Metastasis by Photosensitizer‐Modified Red Blood Cell Membrane‐Coated Nanoparticle

Lang

Zheng

et al. 2022

Adv Funct Materials

View full text Add to dashboard Cite

The red blood cell membrane (RBCm) provides tight protection, lowers the immunogenicity, and prolongs the circulation time of drugs in vivo when acting as the coating of drug delivery systems. However, the cellular uptake and release of drugs are hindered by RBCm. Docetaxel (DTX) is the first-line medicine for treating triple-negative breast cancer (TNBC), but it induces tumor metastasis. To solve these dilemmas, in this study, the photosensitizer 1,1-dioctadecyl-3,3,3,3-tetramethylindotricarbocyanine iodide (DiR)-modified RBCm (DM) is prepared, which is coated onto a hybrid micelle consisting of the prodrugs of DTX and the anti-metastasis agent calcitriol (CTL), obtaining a nanoparticle, named HDC-DM. In a 4T1 tumor-bearing mouse model, after injecting HDC-DM, the intratumoral DTX and CTL concentrations are increased by 1.7 and 2.5 times compared with the free drug groups. After irradiating tumors with near-infrared laser, DiR elicits the photothermal effect, triggering the rupture of RBCm and drug release, promoting drug penetration in tumors, and inducing immunogenic cell death. The tumor growth inhibition rate is 77%, and the formation of lung metastases is reduced by 82%, with good biocompatibility. It is suggested that the combination of phototherapy, chemotherapy, and anti-metastatic therapy using HDC-DM is expected to be a powerful strategy for treating TNBC.

show abstract

Section: Resultsmentioning

confidence: 99%

Promote Intratumoral Drug Release and Penetration to Counteract Docetaxel‐Induced Metastasis by Photosensitizer‐Modified Red Blood Cell Membrane‐Coated Nanoparticle

Lang

Zheng

et al. 2022

Adv Funct Materials

View full text Add to dashboard Cite

show abstract

“…Stimulatory signals released by specific stimuli in the TME, such as tumor, immune, and stromal cells, can transform TAMs from one phenotype to another. For example, CXCL12 secreted by monocytes can repolarize M1-type TAMs to M2-type, making them key stromal cells in the TME that exert immunosuppressive functions and promote tumor progression and therapeutic resistance [ 188 ]. This provides research ideas for reprogramming TAMs to be anti-cancerous.…”

Section: Strategies For Targeting Macrophages In the Treatment Of Sol...mentioning

confidence: 99%

Targeting macrophages: a novel treatment strategy in solid tumors

Liu

Song

et al. 2022

J Transl Med

View full text Add to dashboard Cite

In the tumor microenvironment (TME), tumor-associated macrophages (TAMs) are the most abundant immune cells, which act as a key regulator in tumorigenesis and progression. Increasing evidence have demonstrated that the TME alters the nature of macrophages to maintain dynamic tissue homeostasis, allowing TAMs to acquire the ability to stimulate angiogenesis, promote tumor metastasis and recurrence, and suppress anti-tumor immune responses. Furthermore, tumors with high TAM infiltration have poor prognoses and are resistant to treatment. In the field of solid tumor, the exploration of tumor-promoting mechanisms of TAMs has attracted much attention and targeting TAMs has emerged as a promising immunotherapeutic strategy. Currently, the most common therapeutic options for targeting TAMs are as follows: the deletion of TAMs, the inhibition of TAMs recruitment, the release of phagocytosis by TAMs, and the reprogramming of macrophages to remodel their anti-tumor capacity. Promisingly, the study of chimeric antigen receptor macrophages (CAR-Ms) may provide even greater benefit for patients with solid tumors. In this review, we discuss how TAMs promote the progression of solid tumors as well as summarize emerging immunotherapeutic strategies that targeting macrophages.

show abstract

“…It has been shown that the CXCR4 and CCL2 axis promotes intraosseous PCa cell growth. 33 The treatment with the CXCR4 antagonist plerixafor has been reported to decrease intratibial tumor growth when administered simultaneously with the tumor cell injection whereas it shows not therapeutic effects in already established tumors. 34 This may indicate that the CXCR4 axis is important for bone homing, but not for colonization.…”

Section: Discussionmentioning

confidence: 99%

“…Early diagnosis of bone metastatic spread in PCa patients is critical to improve clinical prognosis. It has been shown that the CXCR4 and CCL2 axis promotes intraosseous PCa cell growth 33 . The treatment with the CXCR4 antagonist plerixafor has been reported to decrease intratibial tumor growth when administered simultaneously with the tumor cell injection whereas it shows not therapeutic effects in already established tumors 34 .…”

Section: Discussionmentioning

confidence: 99%

Dynamics of CXCR4 positive circulating tumor cells in prostate cancer patients during radiotherapy

Klusa

Lohaus

Franken

et al. 2023

Intl Journal of Cancer

View full text Add to dashboard Cite

Ablative radiotherapy is a highly efficient treatment modality for patients with metastatic prostate cancer (PCa). However, a subset of patients does not respond. Currently, this subgroup with bad prognosis cannot be identified before disease progression. We hypothesize that markers indicative of radioresistance, stemness and/or bone tropism may have a prognostic potential to identify patients profiting from metastases‐directed radiotherapy. Therefore, circulating tumor cells (CTCs) were analyzed in patients with metastatic PCa (n = 24) during radiotherapy with CellSearch, multicolor flow cytometry and imaging cytometry. Analysis of copy‐number alteration indicates a polyclonal CTC population that changes after radiotherapy. CTCs were found in 8 out of 24 patients (33.3%) and were associated with a shorter time to biochemical progression after radiotherapy. Whereas the total CTC count dropped after radiotherapy, a chemokine receptor CXCR4‐expressing subpopulation representing 28.6% of the total CTC population remained stable up to 3 months. At once, we observed higher chemokine CCL2 plasma concentrations and proinflammatory monocytes. Additional functional analyses demonstrated key roles of CXCR4 and CCL2 for cellular radiosensitivity, tumorigenicity and stem‐like potential in vitro and in vivo. Moreover, a high CXCR4 and CCL2 expression was found in bone metastasis biopsies of PCa patients. In summary, panCK+CXCR4+ CTCs may have a prognostic potential in patients with metastatic PCa treated with metastasis‐directed radiotherapy.

show abstract

The multifaceted roles of the chemokines CCL2 and CXCL12 in osteophilic metastatic cancers

Cited by 17 publications

References 194 publications

Promote Intratumoral Drug Release and Penetration to Counteract Docetaxel‐Induced Metastasis by Photosensitizer‐Modified Red Blood Cell Membrane‐Coated Nanoparticle

Promote Intratumoral Drug Release and Penetration to Counteract Docetaxel‐Induced Metastasis by Photosensitizer‐Modified Red Blood Cell Membrane‐Coated Nanoparticle

Targeting macrophages: a novel treatment strategy in solid tumors

Dynamics of CXCR4 positive circulating tumor cells in prostate cancer patients during radiotherapy

Contact Info

Product

Resources

About